טוען...

Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAF(V600E) targeted inhibition in a novel syngeneic murine glioma model

Inhibitors of BRAF(V600E) kinase are currently under investigations in preclinical and clinical studies involving BRAF(V600E) glioma. Studies demonstrated clinical response to such individualized therapy in the majority of patients whereas in some patients tumors continue to grow despite treatment....

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Oncotarget
Main Authors: Grossauer, Stefan, Koeck, Katharina, Murphy, Nicole E., Meyers, Ian D., Daynac, Mathieu, Truffaux, Nathalene, Truong, Albert Y., Nicolaides, Theodore P., McMahon, Martin, Berger, Mitchel S., Phillips, Joanna J., James, David C., Petritsch, Claudia K.
פורמט: Artigo
שפה:Inglês
יצא לאור: Impact Journals LLC 2016
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5342782/
https://ncbi.nlm.nih.gov/pubmed/27713119
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12419
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!